Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma-Reference-Cited by-同舟云学术

Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma

Published:2018-04-17 Issue:5 Volume:109 Page:1552-1561
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Iida Shinsuke¹^ORCID,Wakabayashi Masashi²,Tsukasaki Kunihiro³,Miyamoto Kenichi²,Maruyama Dai⁴^ORCID,Yamamoto Kazuhito⁵,Takatsuka Yoshifusa⁶,Kusumoto Shigeru¹,Kuroda Junya⁷,Ando Kiyoshi⁸,Kikukawa Yoshitaka⁹,Masaki Yasufumi¹⁰,Kobayashi Miki¹¹,Hanamura Ichiro¹²,Asai Hiroaki¹³,Nagai Hirokazu¹⁴,Shimada Kazuyuki¹⁵,Tsukamoto Norifumi¹⁶,Inoue Yoshiko¹⁷,Tobinai Kensei⁴

Affiliation:

1. Department of Hematology and Oncology Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG‐LSG) Nagoya City University Hospital Nagoya Japan

2. JCOG Data Center/Operations Office National Cancer Center Tokyo Japan

3. Department of Hematology Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG‐LSG) National Cancer Center Hospital East Kashiwa Japan

4. Department of Hematology Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG‐LSG) National Cancer Center Hospital Tokyo Japan

5. Department of Hematology and Cell Therapy Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG‐LSG) Aichi Cancer Center Hospital Nagoya Japan

6. Department of Hematology Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG‐LSG) Imamura General Hospital Kagoshima Japan

7. Division of Hematology and Oncology Department of Medicine Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG‐LSG) Kyoto Prefectural University Kyoto Japan

8. Department of Hematology and Oncology Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG‐LSG) Tokai University of School of Medicine Isehara Japan

9. Department of Hematology Rheumatology and Infectious Diseases Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG‐LSG) Kumamoto University Hospital Kumamoto Japan

10. Department of Hematology and Immunology Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG‐LSG) Kanazawa Medical University Kahoku Japan

11. Department of Hematology and Oncology Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG‐LSG) Japanese Red Cross Nagoya Daini Hospital Nagoya Japan

12. Division of Hematology Department of Internal Medicine Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG‐LSG) Aichi Medical University Nagakute Japan

13. First Department of Internal Medicine Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG‐LSG) Ehime University Hospital Toon Japan

14. Department of Hematology Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG‐LSG) National Hospital Organization Nagoya Medical Center Nagoya Japan

15. Department of Hematology and Oncology Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG‐LSG) Nagoya University Graduate School of Medicine Nagoya Japan

16. Oncology Center Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG‐LSG) Gunma University Hospital Maebashi Japan

17. Department of Hematology Lymphoma Study Group of the Japan Clinical Oncology Group (JCOG‐LSG) National Hospital Organization Kumamoto Medical Center Kumamoto Japan

Funder

Ministry of Health, Labour and Welfare

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.13550

Reference41 articles.

1. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

2. Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma

3. Phase I/II and pharmacokinetic/pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma;Ogawa Y;Cancer Sci,2007

4. Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma

5. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone;Jagannath S;Haematologica,2006

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lenalidomide use in multiple myeloma (Review);Molecular and Clinical Oncology;2023-11-28

2. Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial;BMC Cancer;2023-10-14

3. Effect modification in network meta-analyses for relapsed/refractory multiple myeloma: systematic review and meta-analysis;BMJ Open;2023-08

4. Relapsed and refractory multiple myeloma: A systematic review and network meta‐analysis of the efficacy of novel therapies;British Journal of Haematology;2023-01-20

5. Effect modification in network meta-analyses of treatments for relapsing refractory multiple myeloma (RRMM): systematic review, meta-analysis, and simulation;2022-05-16